Join Growin Stock Community!

Astrazeneca plcAZN.US Overview

US StockHealthcare
(No presentation for AZN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

AZN AI Insights

AZN Overall Performance

AZN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

AZN Recent Performance

-2.18%

Astrazeneca plc

0.05%

Avg of Sector

-0.31%

S&P500

AZN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

AZN Key Information

AZN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

AZN Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Price of AZN

AZN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

AZN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
3.30
PE Ratio (TTM)
31.82
Forward PE
42.26
PS Ratio (TTM)
5.50
PB Ratio
6.50
Price-to-FCF
53.68
METRIC
VALUE
vs. INDUSTRY
Gross Margin
81.90%
Net Margin
17.41%
Revenue Growth (YoY)
8.63%
Profit Growth (YoY)
9.67%
3-Year Revenue Growth
11.42%
3-Year Profit Growth
14.24%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
3.30
PE Ratio (TTM)
31.82
Forward PE
42.26
PS Ratio (TTM)
5.50
PB Ratio
6.50
Price-to-FCF
53.68
Gross Margin
81.90%
Net Margin
17.41%
Revenue Growth (YoY)
8.63%
Profit Growth (YoY)
9.67%
3-Year Revenue Growth
11.42%
3-Year Profit Growth
14.24%

  • When is AZN's latest earnings report released?

    The most recent financial report for Astrazeneca plc (AZN) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating AZN's short-term business performance and financial health. For the latest updates on AZN's earnings releases, visit this page regularly.

  • Where does AZN fall in the P/E River chart?

    According to historical valuation range analysis, Astrazeneca plc (AZN)'s current price-to-earnings (P/E) ratio is 31.34, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of AZN?

    According to the latest financial report, Astrazeneca plc (AZN) reported an Operating Profit of 2.98B with an Operating Margin of 19.21% this period, representing a growth of 46.27% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is AZN's revenue growth?

    In the latest financial report, Astrazeneca plc (AZN) announced revenue of 15.5B, with a Year-Over-Year growth rate of 4.11%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does AZN have?

    As of the end of the reporting period, Astrazeneca plc (AZN) had total debt of 29.62B, with a debt ratio of 0.26. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does AZN have?

    At the end of the period, Astrazeneca plc (AZN) held Total Cash and Cash Equivalents of 5.71B, accounting for 0.05 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does AZN go with three margins increasing?

    In the latest report, Astrazeneca plc (AZN) achieved the “three margins increasing” benchmark, with a gross margin of 79.9%%, operating margin of 19.21%%, and net margin of 15%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess AZN's profit trajectory and future growth potential.

  • Is AZN's EPS continuing to grow?

    According to the past four quarterly reports, Astrazeneca plc (AZN)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.5. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of AZN?

    Astrazeneca plc (AZN)'s Free Cash Flow (FCF) for the period is 1.31B, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 40.53% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of AZN?

    The latest valuation data shows Astrazeneca plc (AZN) has a Price-To-Earnings (PE) ratio of 31.34 and a Price/Earnings-To-Growth (PEG) ratio of -7.94. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.